Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1282 • ACR Convergence 2020
The Impact of High Disease Activity as Measured by SLEDAI and Drug Burden on Healthcare Utilization, Quality of Life and Work Productivity in Systemic Lupus Erythematosus Patients
Zahi Touma¹, Benjamin Hoskin², Christian Atkinson², David Bell³, James Pike², Jennifer Lofland⁴, Pamela Berry⁵, Chetan Karyekar⁵ and Karen Costenbader⁶, ¹University of Toronto, Toronto, ON, Canada, ²ADELPHI REAL WORLD, Bollington, United Kingdom, ³ADELPHI REAL WORLD, Bollington, Macclesfield, United Kingdom, ⁴Janssen Global Market Access, horsham, PA, ⁵Janssen Global Services, LLC, Horsham, PA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Although there is abundant literature on healthcare utilization in SLE patients, the impact of disease activity in SLE patients is not well understood.To quantify…
Abstract Number: 1298 • ACR Convergence 2020
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Maria Schletzbaum¹, Nnenna Ezeh², Trevor McKown³, Shivani Garg⁴ and Christie Bartels⁵, ¹University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, ³William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁴UW Madison, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…
Abstract Number: 1508 • ACR Convergence 2020
Blood-Brain Barrier Leakage in Systemic Lupus Erythematosus Is Associated with Gray Matter Loss and Cognitive Impairment
Lyna Kamintsky¹, Steven Beyea², John Fisk², Javeria Hashmi², Antonina Omisade², Cynthia Calkin², Tim Bardouille², Chris Bowen², Maher Quraan², Arnold Mitnitski², Kara Matheson², Alon Friedman² and John Hanly³, ¹Department of Medical Neuroscience, Dalhousie University, Halifax, Canada, ²Dalhousie University, Halifax, Canada, ³Dalhousie University, Halifax, NS, Canada
Background/Purpose: Cognitive impairment is the most frequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), yet the mechanisms underlying it remain poorly understood. The purpose of…
Abstract Number: 1665 • ACR Convergence 2020
Sociodemographic and Clinical Predictors of Childhood-Onset SLE Disease Activity in the Childhood Arthritis and Rheumatology Research Alliance Registry
Emily Smitherman¹, Rouba Chahine¹, Timothy Beukelman¹, Andrea Knight², AKM Rahman¹, Mary Beth Son³, Jeffrey R Curtis⁴ and Aimee Hersh⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Boston Children's Hospital, Boston, MA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for early morbidity and mortality, but predictors of moderate/high cSLE disease activity have…
Abstract Number: 1765 • ACR Convergence 2020
Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease
Chelsey Smith¹, Christina Chambers¹, Rebecca Baer², Laura Jelliffe-Pawlowski³ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, ³University of California San Francisco, San Francisco
Background/Purpose: Very young maternal age has been described as a risk factor for several adverse obstetric outcomes. This study aimed to investigate whether younger women…
Abstract Number: 1796 • ACR Convergence 2020
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
Jennifer Davies¹, Emil Carlsson¹, Angela Midgley¹, Eve Smith¹, Ian Bruce², Michael Beresford¹ and Christian Hedrich³, ¹Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, ²Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…
Abstract Number: 1814 • ACR Convergence 2020
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
Shudan Wang¹, Erica Moore², Brianna Lally³, Beatrice Goilav⁴, Chaim Putterman³ and Anna Broder⁵, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, NY, ⁴The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 1951 • ACR Convergence 2020
Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus
Keiko Yoshimoto¹, Katsuya Suzuki¹, Noriyasu Seki², Shuntaro Saito³, Jun Kikuchi¹ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Fractalkine (FKN) binds its receptor, CX3CR1 and accelerates chemotaxis of immune cells by inducing cell surface molecules and mediating adhesion of the cells to…
Abstract Number: 0251 • ACR Convergence 2020
Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
May Choi¹, Marvin Fritzler², Karen Costenbader³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St. Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Díaz⁹, F Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul Fortin¹⁶, Dafna Gladman¹⁷, Ian Bruce¹⁸, Michelle Petri¹⁹, Ellen M Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jönsen²⁴, Graciela Alarcón²⁵, Ronald F Van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, S. Sam Lim³⁰, Murat Inanc³¹, Kenneth Kalunian³², Søren Jacobsen³³, Christine Peschken³⁴, Diane Kamen³⁵, Anca Askanase³⁶ and Ann Clarke³⁷, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷McGill University, Montreal, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ¹²Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹³Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, ²⁰SUNY Downstate Health Sciences University, Brooklyn, ²¹University of North Carolina, Chapel Hill, NC, ²²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²³Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Lund University, Lund, Sweden, ²⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Hospital Universitario Cruces, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³²University of California San Diego, La Jolla, CA, ³³University of Copenhagen, Copenhagen, Denmark, ³⁴Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁵Medical University of South Carolina, Charleston, SC, ³⁶Columbia University College of Physicians and Surgeons, New York, NY, ³⁷University of Calgary, Calgary, Canada
Background/Purpose: ANA testing as an approach to diagnosing and classifying SLE, now embedded in the EULAR/ACR Criteria, is more important than ever. Cross-sectional studies indicate…
Abstract Number: 0268 • ACR Convergence 2020
Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
Zahi Touma¹, Benjamin Hoskin², Christian Atkinson², David Bell³, James Pike², Jennifer Lofland⁴, Pamela Berry⁵, Chetan Karyekar⁵ and Karen Costenbader⁶, ¹University of Toronto, Toronto, ON, Canada, ²ADELPHI REAL WORLD, Bollington, United Kingdom, ³ADELPHI REAL WORLD, Bollington, Macclesfield, United Kingdom, ⁴Janssen Global Market Access, horsham, PA, ⁵Janssen Global Services, LLC, Horsham, PA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The effect of flares on healthcare resource usage and patient-reported outcome scores in SLE patients is not well quantified.To understand how flares impact healthcare…
Abstract Number: 0285 • ACR Convergence 2020
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
Michelle Huang¹, Ariel Stock¹ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 0498 • ACR Convergence 2020
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
Chaim Putterman¹, Elise Mike¹ and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute…
Abstract Number: 0618 • ACR Convergence 2020
The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus
Trevor Faith¹, Ashley White¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: The United States has a deficit of rheumatology specialists. This leads to an increased burden accessing care for patients with autoimmune and connective tissue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].